URB937 是口服有效的、外周限制的 FAAH 抑制剂，IC₅₀ 值为 26.8 nM，可增加 anandamide 水平。URB937 不能影响脑内 FAAH 水平 (无法透过血脑屏障)。

URB937 is an orally active and peripherally restricted FAAH inhibitor (IC 50 =26.8 nM) and increases anandamide levels. URB937 fails to affect FAAH activity in the brain (not penetrate the blood-brain barrier).

Solid

IC50: 26.8 nM (FAAH).

URB937 is actively extruded from the CNS by the ATP-binding cassette (ABC) membrane transporter, Abcg2. has not independently confirmed the accuracy of these methods. They are for reference only.

URB937 (1 mg/kg, i.p.) administrated in mice increases anandamide levels in peripheral tissues, but not forebrain or hypothalamus.
URB937 (1 mg/kg, s.c.) suppresses pain responses elicited by i.p. injections of acetic acid.
URB937 in male rats (an oral dose 3 mg/kg, F = 36%) is absorbed at a moderate rate and displays a peak plasma concentration (C max ) of 159.47 ng/ml, which was achieved one hour after administration. URB937 exhibits T 1/2 of 60 min by an oral dose of 3 mg/kg.
URB937 produces a high degree of antinociception in female mice and rats in models of visceral and inflammatory pain. Moreover, the compound displayed a restricted access to placental and fetal tissues in pregnant mice and rats.
URB937 (1 mg/kg, every 2 days for 30 days) attenuates radiation-induced lung injury and increased endocannabinoid concentration in lung tissu

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Jason R Clapper, et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci. 2010 Oct;13(10):1265-70.
[2]. Valentina Vozella, et al. Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase (FAAH) inhibitor, in rats. J Pharm Pharmacol. 2019 Dec;71(12):1762-1773.

In Vitro: DMSO : 250 mg/mL (705.42 mM; Need ultrasonic)配制储备液